The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | LINKER-MM1: linvoseltamab, a bispecific antibody, in R/R multiple myeloma
Madhav Dhodapkar, MBBS, Emory University School of Medicine, Atlanta, GA, provides an overview of the Phase II LINKER-MM1 trial (NCT03761108), which assessed the BCMA×CD3 bispecific antibody linvoseltamab in heavily pretreated patients with relapsed/refractory (R/R) multiple myeloma. Promising efficacy was reported, where multiple very good partial responses (VGPR) were achieved in a majority of patients. The investigational drug additionally was well tolerated, where adverse events were similar to that of similar antibodies. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BMS, Sanofi, Genentech, Lava Therapeutics
